Arbor Biotechnologies

Arbor Biotechnologies: An early-stage life sciences company pioneering the next-generation of genetic medicines. With the most extensive library of CRISPR nucleases in the industry, a deep bench of world-class founders (including gene editing pioneer Feng Zhang) and scientific advisors, and a leadership team with a proven track record of developing novel platforms and therapeutics, Arbor is well-positioned to develop curative genetic medicines for all patients with genetic diseases. Arbor’s pipeline is powered by its proprietary biodiscovery engine, which blends computational search and scientific expertise to discover, screen, and engineer proteins with desirable characteristics at unprecedented scale and speed. Arbor has raised $83 million to date and top investors include ARCH Venture Partners and its strategic collaboration partner, Vertex Pharmaceuticals.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Investment Participation
Series A
Listing
Private
Market Cap
Private
Therapeutic Modalities
Gene editing
Website:
Address:
20 Acorn Park Drive, Suite 500
Cambridge, MA 02140

Company Participants at Fall Private Company Showcase 2021

  • David Cheng, CTO
  • Devyn M. Smith, Ph.D., CEO
  • John Murphy